Lam Y K, Bogen D, Chang R S, Faust K A, Hensens O D, Zink D L, Schwartz C D, Zitano L, Garrity G M, Gagliardi M M
Merck Sharp & Dohme Research Laboratories, Rahway, New Jersey 07065.
J Antibiot (Tokyo). 1991 Jun;44(6):613-25. doi: 10.7164/antibiotics.44.613.
The discovery and physico-chemical characterization of three novel and minor virginiamycin M1 analogs as potent gastrin antagonists from a culture of a strain of Streptomyces olivaceus are described. These analogs are L-156,586, L-156,587 and L-156,588. They are, respectively, 15-dihydro-13,14-anhydro-, 13,14-anhydro- and 13-desoxy-analogs of virginiamycin M1. We also chemically converted virginiamycin M1 (via L-156,587) to L-156,586 and its unnatural epimer, L-156,906. These analogs are competitive and selective antagonists of gastrin and brain cholecystokinin binding at nanomolar concentrations. These are the most potent gastrin/brain cholecystokinin antagonists from natural products. The same compounds showed poor Gram-positive antibiotic activity versus virginiamycin M1. Structurally related Gram-positive antibiotics, griseoviridin and madumycin I, were inactive in gastrin and brain cholecystokinin binding at up to 100 microM.
本文描述了从一株橄榄色链霉菌培养物中发现的三种新型小分子量维吉尼亚霉素M1类似物作为强效胃泌素拮抗剂的过程及其物理化学特性。这些类似物分别为L-156,586、L-156,587和L-156,588。它们分别是维吉尼亚霉素M1的15-二氢-13,14-脱水、13,14-脱水和13-脱氧类似物。我们还通过化学方法将维吉尼亚霉素M1(经由L-156,587)转化为L-156,586及其非天然差向异构体L-156,906。这些类似物在纳摩尔浓度下是胃泌素和脑胆囊收缩素结合的竞争性和选择性拮抗剂。它们是来自天然产物中最有效的胃泌素/脑胆囊收缩素拮抗剂。与维吉尼亚霉素M1相比,相同化合物对革兰氏阳性菌的抗生素活性较差。结构相关的革兰氏阳性抗生素灰绿霉素和马杜霉素I在高达100微摩尔浓度下对胃泌素和脑胆囊收缩素结合无活性。